ArticleTheranostics2022
Reduced splenic uptake on
Article in Theranostics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 23 citations in OpenAlex.
- Lesion-level dual-tracer PET biomarkers predict prognosis in multiple myeloma treated with CXCR4-directed radiopharmaceutical therapy.European journal of nuclear medicine and molecular imaging · 2026Article
- Advances in the application of frailty scoring in the diagnosis and management of elderly patients with multiple myeloma (Review).Oncology reports · 2026Review
- [Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Article
- Optimal acquisition time of [EJNMMI research · 2026Article
- Synthesis, preclinical evaluation and clinical application of a novel heterodimeric tracerEuropean journal of nuclear medicine and molecular imaging · 2026Article
- Physiological distribution and dosimetry of AlBMC medical imaging · 2026Article
- Selection of SUV normalization and reference tissue for quantitative [68Ga]Ga-Pentixafor PET/CT analysis.EJNMMI research · 2026Article
- The CXCR4-targeted theranostics era: a comprehensive review of a decade of progress (2015-2025).Theranostics · 2026Review
- Emerging ImmunoPET probes for precision cancer immunotherapy: molecular targets and translational applications.Frontiers in oncology · 2026Review
- Reduced splenic uptake of [EJNMMI research · 2025Article
- Splenic T2 signal intensity loss on MRI is associated with disease burden in multiple myeloma.European radiology · 2025Article
- Organ Crosstalk: The Role of Spleen.Phenomics (Cham, Switzerland) · 2025Review
- Minimal Residual Disease-Adapted Therapy in Multiple Myeloma: Current Evidence and Opinions.Current oncology reports · 2024Review
- The Clinical Role of CXCR4-Targeted PET on Lymphoproliferative Disorders: A Systematic Review.Journal of clinical medicine · 2024Review
- Advances in PET Imaging of the CXCR4 Receptor: [Seminars in nuclear medicine · 2024Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 8 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Beyond being a key factor for tumor growth and metastasis in human cancer, C-X-C motif chemokine receptor 4 (CXCR4) is also highly expressed by a number of immune cells, allowing for non-invasive read-out of inflammatory activity. With two recent studies reporting on prognostic implications of the spleen signal in diffusion-weighted magnetic resonance imaging in patients with plasma cell dyscrasias, the aim of this study was to correlate splenic
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.